nephrogenex appoints marco taglietti md to board of directors  business wire nephrogenex appoints marco taglietti md to board of directors october    am eastern daylight time research triangle park ncbusiness wirenephrogenex inc nasdaqnrx a pharmaceutical company focused on the development of therapeutics to treat kidney disease today announced the appointment of marco taglietti md to its board of directors dr taglietti has more than  years of experience in senior leadership positions in pharmaceutical research and development most recently at forest laboratories inc “dr taglietti has an impressive track record of leading global rd operations and has overseen the development and worldwide approvals of dozens of important therapeutic products” said nephrogenex chief executive officer pierre legault “we are extremely pleased to have dr taglietti join our board and look forward to the critical perspective he can bring to the clinical development of pyridorin our phase  compound to treat diabetic kidney disease” prior to its recent acquisition dr taglietti served as executive vice president research and development and chief medical officer of forest laboratories inc he also served as president chief medical officer of the forest research institute prior to joining forest labs in 7 dr taglietti held the position of senior vice president head of global research and development at stiefel laboratories inc for three years he joined stiefel after  years at scheringplough corporation where he last held the position of vice president worldwide clinical research for antiinfectives oncology cns endocrinology and dermatology dr taglietti began his career at marion merrell dow research institute over the course of his career he has brought to market  different products in the us and internationally he received his medical degree and board certifications from the university of pavia in italy dr taglietti joins nephrogenex’s board of directors as an independent director serving on the audit and compensation committees about nephrogenex inc nephrogenex nasdaqnrx is a clinicalstage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries since our inception we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates our clinical program has been done in collaboration with world leading clinical investigators in kidney disease our product pipeline includes an oral formulation of pyridorin® pyridoxamine dihydrochloride which is being developed as a chronic therapeutic agent to slow the progression of diabetic nephropathy as well as an intravenous formulation of pyridorin to treat specific types of acute kidney injury cautionary note on forwardlooking statements this press release contains certain statements that are or may be deemed forwardlooking statements within the meaning of the private securities litigation reform act of  forwardlooking statements may be identified by words such as expects intends anticipates plans believes seeks estimates will or words of similar meaning and include but are not limited to statements regarding the outlook for our future business and financial performance forwardlooking statements are based on our current expectations and assumptions which are subject to inherent uncertainties risks and changes in circumstances that are difficult to predict actual outcomes and results may differ materially from those in the forwardlooking statements due to global political economic business competitive market regulatory and other factors and risks including the items identified under part i—item a—risk factors of our annual report on form k for the year ended december   filed with the securities and exchange commission sec on march   as well as in other filings that we may make with the sec in the future the forwardlooking statements contained in this press release reflect our current views with respect to future events and we do not undertake and specifically disclaim any obligation to update any forwardlooking statements   contacts investorsthe trout groupmichael levitan mlevitantroutgroupcomormediabmc communicationssusan duffy sduffybmccommunicationscom contacts investorsthe trout groupmichael levitan mlevitantroutgroupcomormediabmc communicationssusan duffy sduffybmccommunicationscom search advanced news search advanced news search log in sign up marco taglietti  forest laboratories  inc  zoominfocom marco taglietti scynexis inc profile  biography  bloomberg feedback marco taglietti presidentceo scynexis inc career history presidentceo scynexis inc present chief executive officer scynexis inc  exec vpdrug devchief medical ofcr forest laboratories inc  senior vpresearch  development forest laboratories inc  vpresearch  development forest laboratories inc  vpresearch  chief medical ofcr forest research inst inc 7 senior vpheadglobal research stiefel laboratories inc unknown7 president forest research inst inc unknown senior vpheadglobal research stiefel laboratories inc former vpworldwide clinical research scheringplough corppremerger with merck  co inc former show more website wwwscynexiscom corporate information address  hudson st suite  jersey city nj  united states phone  fax  web url wwwscynexiscom from the web personal information education university of pavia md memberships board memberships delcath systems inc board member present scynexis inc board member present nephrogenex inc board member 7 show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext7 about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext77 where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext77 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext77 personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext77 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext7 legal privacy  cookies  7 microsoft scynexis names marco taglietti md chief executive officer nasdaqscyx facebook google linkedin twitter email rss feb   previous release  next release pdf add to briefcase file is in briefcase scynexis names marco taglietti md chief executive officer yves ribeill phd to remain president serve on board of directorscarole sable md submits resignation as chief medical officer research triangle park nc feb   globe newswire  drug discovery and development company scynexis inc nasdaqscyx announced today that its board of directors has appointed marco taglietti md as the companys chief executive officer effective april   dr taglietti a member of the scynexis board of directors will succeed yves ribeill phd dr ribeill will remain the companys president and will continue to serve on the scynexis board of directors in an unrelated matter carole sable md the companys current chief medical officer is stepping down effective february   yves provided remarkable leadership over the last  years building a strong drug discovery organization and successfully ushering scy7 into clinical development said pamela j kirby phd chairman of the board of scynexis yves will remain a key member of the management team as we transition marcos role at scynexis to chief executive officer marco brings to the position an outstanding background and relevant experience in drug development having led more than  drugs and devices through clinical development and onto the market including several antiinfective products scynexis is a company with great people products and potential and i am honored and excited by taking over the role of ceo said marco taglietti md scy7 has tremendous potential to play an important role in the treatment of lifethreatening fungal infections i look forward to advancing the drugs clinical development as a potential new treatment option to those patients who currently experience high morbidity and mortality dr taglietti was appointed to the scynexis board of directors in december  he previously served as executive vice president research and development and chief medical officer of forest laboratories inc and also as president of the forest research institute until the company was acquired by actavis plc prior to joining forest labs dr taglietti was senior vice president head of global research and development at stiefel laboratories inc and held various positions with scheringplough corporation where he served as vice president worldwide clinical research for antiinfectives oncology cns endocrinology and dermatology he received his medical degree and his board certification in infectious diseases from the university of pavia in italy i have tremendous faith in marcos ability to lead scynexis into the future and look forward to working closely with him as we continue to advance the development of our lead compound for the treatment of invasive fungal infections said yves ribeill  i also want to thank carole for her work in getting scy7 back into the clinic and wish her the best in her next endeavorabout scynexis scynexis is a pharmaceutical company committed to the discovery development and commercialization of novel antiinfectives to address significant unmet therapeutic needs we are developing our lead product candidate scy7 as an oral and intravenous iv drug for the treatment of serious and lifethreatening invasive fungal infections in humans for more information visit wwwscynexiscomforward looking statement statements contained in this press release regarding matters that are expected to occur in the future are forwardlooking statements within the meaning of the private securities litigation reform act of  because such statements are subject to risks and uncertainties actual results may differ materially from those expressed or implied by such forwardlooking statements risks are described more fully in scynexiss filings with the securities and exchange commission including without limitation its most recent quarterly report on form q and other documents subsequently filed with or furnished to the securities and exchange commission all forwardlooking statements contained in this press release speak only as of the date on which they were made scynexis undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were madecontact investor relations jillian connell the trout group llc tel  email jconnelltroutgroupcom media relations heather savelle macdougall biomedical communications tel 7 hsavellemacbiocomcom scynexis inc contact chuck osborne chief financial officer tel  chuckosbornescynexiscom microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext7 about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext77 where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext77 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext77 personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext77 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext7 legal privacy  cookies  7 microsoft i taglietti  manufacturer ponte san marco  calcinato  italy login oppure facebook login all people projects blogs photos sign up share and discover architectureand interior design i taglietti manufacturer ponte san marco  calcinato  italy follow following unfollow   followers 7 visits contact follow following unfollow  i taglietti followers project year view all status view all i taglietti address via sibilla aleramo   ponte san marco  calcinato  italy tel   fax  7 advertising